Big Bet in Jammu & Kashmir: Orchid Pharma Invests ₹600 Crore in New Plant

Orchid Pharma Limited is set to embark on an ambitious project to produce 7-Aminocephalosporanic Acid at their new facility in Jammu, Jammu & Kashmir. With an investment of 600 Crores, the project aims to achieve a production capacity of 1000 tonnes per annum.

The new facility is strategically located to leverage the benefits of Jammu & Kashmir's evolving industrial landscape. This location was chosen for its logistical advantages and the availability of a skilled workforce, which is crucial for pharmaceutical manufacturing.

7-Aminocephalosporanic Acid, or 7-ACA, is a vital component used in the synthesis of cephalosporin antibiotics, which are among the most widely prescribed antibiotics due to their effectiveness against a broad range of bacterial infections. The demand for 7-ACA is consistently strong, making this project not only viable but also potentially very profitable.

Orchid Pharma's project includes state-of-the-art equipment and technology to ensure high-quality production standards. The plant is designed to be environmentally friendly, incorporating waste treatment facilities and measures to minimize environmental impact.

Upon completion, the project is expected to significantly boost Orchid Pharma's position in the global pharmaceutical market, particularly in the antibiotics segment. It will also contribute to the local economy by creating job opportunities and fostering related businesses in the region.

News by Rahul Yelligetti